Abstract
The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as reflected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR . 1995 J. Biol. Chem. 270: 27489–27494
Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH . 1995 Oncogene 10: 1813–1821
Altiok N, Altiok S, Changeux JP . 1997 EMBO J. 16: 717–725
Antonyak MA, Moscatello DK, Wong AJ . 1998 J. Biol. Chem. 273: 2817–2822
Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE . 1995 Mol. Cell. Biol. 15: 6496–6505
Beerli RR, Hynes NE . 1996 J. Biol. Chem. 271: 6071–6076
Brattain M, Levine A, Chakrabarty S, Yeoman L, Willson J, Long B . 1984 Cancer Metastasis Rev. 3: 177–184
Carpenter CL, Cantley LC . 1996 Curr. Opin. Cell Biol. 8: 153–158
Carraway III KL, Cantley LC . 1994 Cell 78: 5–8
Cobb MH, Goldsmith EJ . 1995 J. Biol. Chem. 270: 14843–14846
Coffer PJ, Jin J, Woodgett JR . 1998 Biochem. J. 335: 1–13
Coffey Jr RJ, Sipes NJ, Bascom CC, Graves-Deal R, Pennington CY, Weissman BE, Moses HL . 1988 Cancer Res. 48: 1596–1602
Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE . 1997 Cancer Res. 57: 3804–3811
Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR . 1995 Proc. Natl. Acad. Sci. USA 92: 7686–7689
Egan SE, Weinberg RA . 1993 Nature 365: 781–783
Goldie JH, Coldman AJ . 1979 Cancer Treat. Rep. 63: 1727–1733
Grammer TC, Cheatham L, Chou MM, Blenis J . 1996 Cancer Surv. 27: 271–292
Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655
Graus-Porta D, Beerli RR, Hynes NE . 1995 Mol. Cell. Biol. 15: 1182–1191
Gullick WJ . 1996 Cancer Surv. 27: 339–349
Howell GM, Humphrey LE, Awwad RA, Wang D, Koterba A, Periyasamy B, Yang J, Li W, Willson JK, Ziober BL, Coleman K, Carboni J, Lynch M, Brattain MG . 1998 J. Biol. Chem. 273: 9214–9223
Hsu SM, Raine L, Fanger H . 1981 Am. J. Clin. Pathol. 75: 816–821
Hudziak RM, Schlessinger J, Ullrich A . 1987 Proc. Natl. Acad. Sci. USA 84: 7159–7163
Jiang D, Yang H, Willson JK, Liang J, Humphrey LE, Zborowska E, Wang D, Foster J, Fan R, Brattain MG . 1998 J. Biol. Chem. 273: 31471–31479
Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R . 1997 Gastroenterology 112: 1103–1113
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y . 1996 EMBO J. 15: 254–264
Klapper LN, Kirschbaum MH, Sela M, Yarden Y . 2000 Adv. Cancer Res. 77: 25–79
Kristt DA, Yarden Y . 1996 Cancer 78: 1272–1283
Levitzki A, Gazit A . 1995 Science 267: 1782–1788
Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX . 1996 Cancer Res. 56: 1457–1465
Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JK . 1990 J. Clin. Invest. 86: 356–362
Marte BM, Jescke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE . 1995 Mol. Endocrinol. 9: 14–23
Morali F, Cattabeni M, Tagliabue E, Campiglio M, Menard S, Marzola M, Lucchini V, Colombo N, Mangioni C, Redaelli L . 1993 Ann. Oncol. 4: 775–779
Moscatello D, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ . 1998 J. Biol. Chem. 273: 200–206
Mulder KM, Brattain MG . 1989 J. Cell Physiol. 138: 450–458
Noguchi H, Sakamoto C, Wada K, Akamatsu T, Uchida T, Tatsuguchi A, Matsui H, Fukui H, Fujimori T, Kasuga M . 1999 Gastroenterology 117: 1119–1127
Olayioye MA, Neve RM, Lane HA, Hynes NE . 2000 EMBO J. 19: 3159–3167
Pang L, Sawada T, Decker SJ, Saltiel AR . 1995 J. Biol. Chem. 270: 13585–13588
Pittelkow MR, Cook PW, Shipley GD, Derynck R, Coffey Jr RJ . 1993 Cell Growth Differ. 4: 513–521
Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S . 1993 Nature 366: 473–475
Qiu Y, Ravi L, Kung HJ . 1998 Nature 393: 83–85
Ram TG, Ethier SP . 1996 Cell Growth Differ. 7: 551–561
Riese II DJ, Stern DF . 1998 Bioessays 20: 41–48
Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S, Tahara E . 1995 Jpn. J. Clin. Oncol. 25: 240–249
Scoccia B, Lee YM, Niederberger C, Ilekis JV . 1998 J. Soc. Gynecol. Investig. 5: 161–165
Shi SR, Key ME, Kalra KL . 1991 J. Histochem. Cytochem. 39: 741–748
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A . 1989 Science 244: 707–712
Sporn MB, Todaro GJ . 1980 N. Engl. J. Med. 303: 878–880
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y . 1996 Mol. Cell. Biol. 16: 5276–5287
van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R . 1988 Oncogene 2: 175–178
Vlahos CJ, Matter WF, Brown RF, Traynor-Kaplan AE, Heyworth PG, Prossnitz ER, Ye RD, Marder P, Schelm JA, Rothfuss KJ . 1995 J. Immunol. 154: 2413–2422
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A . 1995 EMBO J. 14: 4267–4275
Worthylake R, Opresko LK, Wiley HS . 1999 J. Biol. Chem. 274: 8865–8874
Worthylake R, Wiley HS . 1997 J. Biol. Chem. 272: 8594–8601
Acknowledgements
This work was supported by NIH grants CA 34432, CA 54807 (MG Brattain), CA 68316 (JKV Willson) and CA84337-01A1 (DM Dawson).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Venkateswarlu, S., Dawson, D., Clair, P. et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21, 78–86 (2002). https://doi.org/10.1038/sj.onc.1205011
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205011
Keywords
This article is cited by
-
Affibody-mediated PET imaging of HER3 expression in malignant tumours
Scientific Reports (2015)
-
Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
BMC Cancer (2014)
-
Tributyrin emulsion as a potent inhibitor of serum- or heregulin-stimulated proliferation of colon cancer cells
Journal of Pharmaceutical Investigation (2012)
-
Expression of NRG1 and its receptors in human bladder cancer
British Journal of Cancer (2011)
-
The ERBB3 receptor in cancer and cancer gene therapy
Cancer Gene Therapy (2008)